Investor Presentaiton
111
Investor presentation
Full year 2022
International Operations at a glance.
Diabetes trend
Million
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
600
400
200
0
M
487
2021
587
2030
Population with diabetes
Diabetes growth rate
DKK
billion
19%
250
17%
Full year 2022
Sales
(mDKK)
Growth²
80%
Total GLP-13
26,196
57%
Long-acting insulin4
11,403
-1%
200
36.7%1
60%
Premix insulin5
10,023
-9%
GLP-1
Fast-acting insulin
10,826
-3%
150
Human insulin
Insulin
6,508
-18%
720
3.9%1
40%
Total insulin
38,760
-7%
100
Other Diabetes care?
2,428
-11%
20%
Diabetes care
67,384
10%
50
8.5%1
OAD
Obesity care8
5,886
82%
0
0%
Diabetes & Obesity
73,270
14%
Nov
2045
2017
Nov
2022
care
Rare disease⁹
12,577
5%
GLP-1 MS
-Insulin MS
-OAD MS
Total
85,847
13%
Novo NordiskⓇ
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific; Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period; Competitor insulin value market
shares, as of Nov 2022: Novo Nordisk 51%, Sanofi 27% and Eli Lilly 13%;
Competitor GLP-1 value market shares, as of Nov 2022: Novo Nordisk
64%, Eli Lilly 34% and AstraZeneca 1%; OAD: Oral anti-diabetic; MS:
Market share; Source: IQVIA MAT, Nov 2022 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and Levemir®: 5 Comprises RyzodegⓇ and
NovoMix®; 6 Comprises FiaspⓇ and NovoRapidⓇ: 7 Comprises Novo NormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®: 9 Comprises
primarily NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, EsperoctⓇ,
Norditropin®, Vagifem® and ActivelleⓇView entire presentation